NASDAQ · CAPR
Capricor Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CAPR: Nov 9, 2026
Capricor Therapeutics, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.61. The reported EPS for the same quarter last year was $-0.54.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.61 | $-0.40 | $-0.74 | 5 |
| Dec 2026 | $0.12 | $3.01 | $-0.73 | 5 |
| Mar 2027 | $-0.48 | $-0.35 | $-0.61 | 2 |
| Jun 2027 | $-0.36 | $-0.23 | $-0.49 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · MarketBeat · Fintel- BNK Invest · Oct 30, 12:18 PM EDTCommit To Buy Capricor Therapeutics At $3, Earn 69.5% Annualized Using OptionsInvestors considering a purchase of Capricor Therapeutics Inc (Symbol: CAPR) shares, but cautious about paying the going market price of $6.33/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in
- RTTNews · Oct 29, 4:01 AM EDTBiotech Stocks Facing FDA Decision In November 2026(RTTNews) – The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.
- RTTNews · Oct 9, 1:37 PM EDTWeekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data(RTTNews) – This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.
- MarketBeat · Oct 7, 7:02 PM EDTCapricor Highlights Two-Year Deramiocel Data as FDA Decision Nears3 Small-Cap Biotechs With Binary Catalysts on the CalendarCapricor Therapeutics (NASDAQ:CAPR) presented updated clinical data for deramiocel in Duchenne muscular dystrophy, or DMD, including two-year open-label extension results from its Phase III HOPE-3 study and additional stat
- RTTNews · Oct 5, 11:27 AM EDTCapricor's Deramiocel Slows Upper Limb Decline In Duchenne Muscular Dystrophy(RTTNews) – Capricor Therapeutics (CAPR) presented new data from the ongoing HOPE-3 open-label extension study showing that Deramiocel continued to slow the decline of upper limb function in patients with Duchenne muscular dystrophy.
- Fintel · Oct 1, 10:47 PM EDTCapricor Therapeutics Average Analyst Price Target Rises 12.70% to $24.14The average one-year price target for Capricor Therapeutics (NASDAQGS:CAPR) (DB:4LN2) has been revised to $24.14 / share. This is an increase of 12.70% from the prior estimate of $21.42 dated September 11, 2026. These figures represent aggregate analyst targets compiled from vari
- NASDAQ.com · Sep 30, 8:28 AM EDTPre-Market Most Active for Sep 30, 2026 : CAPR, SOFI, NOK, TQQQ, TSLL, SQQQ, SNAP, IBIT, NKE, NIO, ORCL, SGOVThe NASDAQ 100 Pre-Market Indicator is up 110.77 to 30,450.1. The total Pre-Market volume is currently 145,772,447 shares traded.The following are the most active stocks for the pre-market session: Capricor Therapeutics, Inc. (CAPR) is +1.15 at $9.72, with 6,147,525 shares trade
- RTTNews · Sep 17, 2:28 PM EDTBiotech Stocks In Focus: Aethlon, Tiziana, Capricor, Firefly & Clearmind(RTTNews) – Biotech stocks were in focus Thursday following a series of company updates, including Aethlon Medical's proposed merger with North Immunology, Tiziana Life Sciences' MS trial collaboration, Capricor's upcoming Duchenne data, Firefly Neuroscience's brain-medicine part
- RTTNews · Sep 17, 12:04 PM EDTCapricor To Present 24-Month HOPE-3 Data At WMS 2026(RTTNews) – Capricor Therapeutics (CAPR) will present new data from its Phase 3 HOPE-3 study and open-label extension (OLE) of deramiocel at the 2026 World Muscle Society Congress, taking place between September 29 and October 3, 2026, in Hiroshima, Japan.
- Fintel · Sep 15, 8:23 AM EDTCapricor Therapeutics Consensus Price Target Increased by 22.33% to $21.42The average one-year price target for Capricor Therapeutics (NASDAQGS:CAPR) has been revised to $21.42 / share. This is an increase of 22.33% from the prior estimate of $17.51 dated August 25, 2026. These figures represent aggregate analyst targets compiled from various institut
- MarketBeat · Sep 13, 10:50 AM EDT3 Small-Cap Biotechs With Binary Catalysts on the CalendarFor small-cap biotech investors, a single date on the calendar can matter more than a quarter's worth of earnings reports. These companies often burn cash for years without product revenue, betting everything on a single clinical trial readout or an FDA decision. When that momen
- Zacks · Sep 7, 9:28 AM EDTCAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?Capricor shares jump in a month as positive phase III data and renewed FDA engagement revive hopes for deramiocel approval in DMD.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Capricor Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.